Thorat T - Search Results

1

Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review.

Duckers J, Lesher B, Thorat T, Lucas E, McGarry LJ, Chandarana K, De Iorio F. Duckers J, et al. Among authors: thorat t. J Clin Med. 2021 Apr 6;10(7):1527. doi: 10.3390/jcm10071527. J Clin Med. 2021. PMID: 33917386 Free PMC article. Review.

2

Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States.

Thorat T, McGarry LJ, Jariwala-Parikh K, Limone B, Bonafede M, Chandarana K, Konstan MW. Thorat T, et al. Pulm Ther. 2021 Jun;7(1):281-293. doi: 10.1007/s41030-021-00154-9. Epub 2021 Apr 28. Pulm Ther. 2021. PMID: 33913076 Free PMC article.

3

VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non-G551D-CFTR gating mutations.

Simmonds NJ, van der Ent CK, Colombo C, Kinnman N, DeSouza C, Thorat T, Chew ML, Chandarana K, Castellani C. Simmonds NJ, et al. Among authors: thorat t. J Cyst Fibros. 2023 Jan;22(1):124-131. doi: 10.1016/j.jcf.2022.05.007. Epub 2022 May 23. J Cyst Fibros. 2023. PMID: 35613999 Free article.

4

Healthcare resource utilization and costs among children with cystic fibrosis in the United States.

Thorat T, McGarry LJ, Bonafede MM, Limone BL, Rubin JL, Jariwala-Parikh K, Konstan MW. Thorat T, et al. Pediatr Pulmonol. 2021 Sep;56(9):2833-2844. doi: 10.1002/ppul.25535. Epub 2021 Jul 7. Pediatr Pulmonol. 2021. PMID: 34138523 Free PMC article.

5

Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis.

Suthoff E, Mainz JG, Cox DW, Thorat T, Grossoehme DH, Fridman M, Sawicki GS, Rosenfeld M. Suthoff E, et al. Among authors: thorat t. J Pediatr. 2019 Dec;215:164-171.e2. doi: 10.1016/j.jpeds.2019.08.038. J Pediatr. 2019. PMID: 31761140

6

Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs.

Chambers JD, Thorat T, Pyo J, Chenoweth M, Neumann PJ. Chambers JD, et al. Among authors: thorat t. Health Aff (Millwood). 2014 Oct;33(10):1751-60. doi: 10.1377/hlthaff.2014.0574. Health Aff (Millwood). 2014. PMID: 25288419

7

Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process.

Chambers JD, Thorat T, Wilkinson CL, Neumann PJ. Chambers JD, et al. Among authors: thorat t. Health Aff (Millwood). 2017 Aug 1;36(8):1408-1415. doi: 10.1377/hlthaff.2016.1541. Health Aff (Millwood). 2017. PMID: 28784733

8

Do Specialty Drugs Offer Greater Value for Money Than Traditional Drugs?

Chambers JD, Thorat T, Chenoweth M, Pyo J, Neumann PJ. Chambers JD, et al. Among authors: thorat t. Value Health. 2014 Nov;17(7):A419-20. doi: 10.1016/j.jval.2014.08.1026. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201059 Free article. No abstract available.

9

Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia.

Thorat T, Neumann PJ, Chambers JD. Thorat T, et al. J Manag Care Spec Pharm. 2018 Jul;24(7):632-642. doi: 10.18553/jmcp.2018.24.7.632. J Manag Care Spec Pharm. 2018. PMID: 29952709 Free PMC article. Review.

10

The lag from FDA approval to published cost-utility evidence.

Chambers JD, Thorat T, Pyo J, Neumann PJ. Chambers JD, et al. Among authors: thorat t. Expert Rev Pharmacoecon Outcomes Res. 2015 Jun;15(3):399-402. doi: 10.1586/14737167.2015.1001371. Epub 2015 Jan 12. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25579324

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters